Incannex Healthcare

JOEL LATHAM

MANAGING DIRECTOR

(ASX:IHL)

◾ Company Name: Incannex Healthcare ◾ Company ASX code: IHL, NASDAQ: IXHL ◾ Key areas: Novel combination cannabinoid pharmaceuticals and psychedelic therapies. ◾ Key Personnel: Joel Latham, Managing Director | Dr Mark Bleackley, Chief Scientific Officer | Rosemarie Walsh, VP, Clinical Operations ◾ Locations: Sydney, Melbourne, Perth, New York ◾ Market Cap as of 15/09/22: $472.31M ◾ 52 Week share price as of 15 September: $0.185 - $0.755 ◾ Company Website: incannex.com.au

COMPANY PROFILE

In the burgeoning area of medicinal cannabis and psychedelic therapy on the ASX, Incannex Healthcare stands out, with a mission to create first-in-class pharmaceutical drugs and therapies for patients with unmet medical needs.

Incannex listed on the ASX in 2016 and in February moved to a dual listing on the Nasdaq, to be accessible to a wider audience of investors with sophisticated understanding of medicinal cannabinoids, psychedelic therapies and pharmaceutical development.

Incannex is developing targeted and scientifically validated fixed-dose combinations of synthetic cannabinoid and psychedelic agents, applying proprietary insights to create long term benefit for patients and shareholders.

The company is focused on developing patented pharmacotherapies (drugs) to the point of FDA registration for prescription by a doctor.

Incannex’s competitive advantage over other medicinal cannabis companies is that its cannabinoid drug candidates are combined with existing off-patent pharmaceuticals to synergistically enhance therapeutic outcomes.

Incannex is undertaking clinical projects for its cannabinoid combination drug candidates designed to treat obstructive sleep apnoea, lung inflammation, rheumatoid arthritis, inflammatory bowel disease, concussion and traumatic brain injury

In partnership with the Clinical Psychedelic Research Lab at Monash University, Incannex is undertaking a Phase II trial investigating psilocybin assisted psychotherapy to treat generalised anxiety disorder (GAD). The trial is considered one of the top 5 most advanced trials in the psychedelic space globally.

Furthermore, Incannex’s portfolio of clinical indications expanded rapidly since its landmark acquisition of APIRx Pharmaceuticals in August, supercharging its technical and drug development capability and patent portfolio.

APIRx researches and develops prescription pharmaceutical cannabinoid medicines with 22 active pre-clinical and clinical projects at various stages of development, underpinned by 19 granted patents and 23 pending patents.

APIRx has cannabinoid treatment candidates for pain management, dementia, Parkinson’s disease, restless leg syndrome, gastrointestinal diseases, periodontitis, addiction disorders, skin, and ophthalmic conditions.

It also has multiple patents for cannabinoid-based drug candidates designed for treatment of addiction to different drug classes including opioid, cannabis and nicotine.

The APRIx acquisition marks possibly the most significant in the medicinal cannabis sector since the takeover of GW Pharmaceuticals (developer of CBD-based Epidiolex) by Jazz Pharmaceuticals for US$7.2B announced in May 2021.

APIRx was established as a corporate entity in the Netherlands to amalgamate the intellectual property assets of medicinal cannabinoid pioneers, and the company’s co-founders Dr George Anastassov and Lekhram Changoer.

The pair have developed the world’s largest privately-held patent portfolio of pharmaceutical cannabinoid inventions, ideas and products.

In a strong vote of confidence in its drug candidates and development strategy, former Pfizer executive and now Novo Nordisk A/S vice president, US regulatory affairs expert Robert B. Clark has joined the Incannex board of directors.

Clark is an international pharmaceutical regulatory heavyweight with more than 38 years of US and global regulatory experience, overseeing FDA approval of 12 new pharmaceutical drugs over the past 10 years. Experience will benefit Incannex as it focuses on US and European programs.

KEY INVESTMENT HIGHLIGHTS

JULY 21, 2022: Incannex earns approval to start a milestone clinical trial into its multiuse, anti-inflammatory drug IHL-675A to treat various inflammatory disorders. AUGUST 5, 2022: Incannex completes the acquisition of APIRx Pharmaceuticals to become the world’s largest holder of patents related to medicinal cannabis product candidates. AUGUST 17, 2022: Incannex appoints former Pfizer executive and now Novo Nordisk A/S Vice President, US regulatory affairs Robert B. Clark as a Non-Executive Director.